Norcoclaurine synthases with increased activity
The invention relates to norcoclaurine synthases and substrate binding sites having one or more site-specific mutation which increase the activity, when compared to the wild type synthase, of the condensation of 4-HPAA and dopamine to (S)-norcoclaurine and/or 3,4-DhPAA and dopamine to (S)-norlaudanosoline. The inventors both identified specific mutations corresponding to at position 73, 75, 77, 82, 99, 114, 141, 142, 147, 152, 174 and/or 178 in the count according to SEQ ID No: 1, and sites corresponding to the binding domains defined in SEQ ID NO: 4 and 5, where the mutated increase of the activity may be positioned within these norcoclaurine synthases. These domains are conserved regions.
1. A variant norcoclaurine synthase comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 1, and which has one or more site-specific substitution corresponding to position 73, 77, 99, 114, 142, 152, 174 and/or 178 of SEQ ID NO: 1.
2. The variant norcoclaurine synthase according to claim 1 , wherein the one or more site-specific substitution is one or more of A73P, A77S, A77E, A77T, Q99K, Q99R, K114E, V142I, K152R, V174E, V174G, V174Q, V174E, I178A, I178S, I178D, I178N, 1178Q, and I178T of SEQ ID NO: 1.
3. The variant norcoclaurine synthase according to claim 1 , wherein the variant norcoclaurine synthase comprises the amino acid sequence HDEL (SEQ ID NO: 22)at the C-terminus of the variant norcoclaurine synthase.
4. The variant norcoclaurine synthase according to claim 1 further comprising a non-functional signal peptide.
5. The variant norcoclaurine synthase according to claim 1 , having an increased catalysation of the condensation of 4-hydroxy-phenylacetaldehyde (4-HPAA) and dopamine to(S)-norcoclaurine and/or 3,4-dihydroxy-acetaldehyde (3,4-DhPAA) and dopamine to(S)-norlaudanosoline when compared to a wild-type synthase of SEQ ID NO: 1.
6. The variant norcoclaurine synthase according to claim 1 , comprising site-specific substitutions at positions 141/142/152, 75/178, or 75/152/178 of SEQ ID NO: 1.
7. The variant norcoclaurine synthase according to claim 6 , wherein the site-specific substitutions are V141I/V142I/K152R, I75L/1178D, 175K/1178D, or I75K/K152R/1178D, of SEQ ID NO: 1.
8. A nucleic acid encoding a norcoclaurine synthase according to claim 1 .
9. The nucleic acid according to claim 8 , wherein the nucleic acid sequence is at least 70% identical to the nucleic acid sequence of SEQ ID NO: 2.
10. The nucleic acid according to claim 8 , wherein the nucleic acid is codon optimized for S. cerevisiae.
11. The nucleic acid according to claim 8 , wherein the nucleic acid sequence is at least 60% identical to the nucleic acid sequence of SEQ ID NO: 3.
12. The nucleic acid according to claim 8 , wherein the nucleic acid sequence is at least 80% identical to the nucleic acid sequence of SEQ ID NO: 3.
13. A heterologous host cell comprising the variant norcoclaurine synthase according to claim 1 , wherein the norcoclaurine synthase is heterologous to the host cell.
14. The heterologous host cell according to claim 13 , wherein the cell is a yeast cell, a plant cell, a mammalian cell, an insect cell, a fungal cell, a bacterial cell, an algal cell, or a cyanobacterial cell.
15. The heterologous host cell according to claim 13 , wherein the cell is a yeast cell selected from the group consisting of Saccharomyces cerevisiae, Schizosaccharomyces pombe, Yarrowia lipolytica, Candida glabrata, Ashbya gossypii, Cyberlindnera jadinii, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha, Candida boidinii, Arxula adeninivorans, Xanthophyllomyces dendrorhous, Candida albicans, Rhodotorula sp., or Rhodospiridium sp.
16. The heterologous host cell according to claim 13 , wherein the host cell is a Saccharomyces.
17. The heterologous host cell according to claim 13 , wherein the host cell is a yeast cell is a Saccharomyces cerevisiae cell.
18. A method for preparing a(S)-norcoclaurine and/or(S)-norlaudanosoline compound, the method comprising the steps of:
providing a recombinant host cell according to claim 13 , capable of catalysing the condensation of 4-hydroxy-phenylacetaldehyde (4-HPAA) and dopamine to(S)-norcoclaurine and/or 3,4-dihydroxy-acetaldehyde (3,4-DhPAA) and dopamine to(S)-norlaudanosoline, and
culturing the cell under conditions promoting said catalysation; and optionally isolating the(S)-norcoclaurine and/or(S)-norlaudanosoline.